HUTCHMED (China) Ltd
HMPL-760
relapsed/refractory diffuse large B-cell lymphoma
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for HMPL-760 in relapsed/refractory diffuse large B-cell lymphoma are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“The trial is a randomized, double-blind, positive controlled Phase III study to evaluate the efficacy, safety, and pharmacokinetics (“PK”) of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in DLBCL patients ”